Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANS014004 in Locally Advanced or Metastatic Solid Tumors
NCT06328439Phase 1Active, not recruiting
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ANS014004 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Avistone Biotechnology Co., Ltd. Primary endpoints: Incidence of Adverse Events at 2 years, Incidence of Serious Adverse Events at 2 years and 3 more. Started May 2024; status: active, not recruiting.
02
Drugs
ANS014004
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06328439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06328439.